Cyclin D1 expression analysis in familial breast cancers may discriminate BRCAX from BRCA2-linked cases

Mara Colombo, Monica Giarola, Luigi Mariani, Carla B. Ripamonti, Virna De Benedetti, Michele Sardella, Marco Losa, Siranoush Manoukian, Bernard Peissel, Marco A. Pierotti, Silvana Pilotti, Paolo Radice

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Most familial breast cancers arise in patients who tested negative for germline mutations in BRCA1 and BRCA2 genes (also referred to as BRCAX cases). Several studies aimed to define histopathological and molecular profiles characteristic of BRCA1, BRCA2 and BRCAX tumors have been performed. Major pathological and immunohistochemical differences have been reported in BRCA1 cancers compared to the other two groups, whereas less difference has been observed between BRCA2 and BRCAX cases. The aim of this study was to investigate the ability of selected tumor markers to discriminate BRCAX breast cancers from cancers arising in carriers of mutations in BRCA genes, and their usefulness in selecting familial cases in whom testing for such mutations is more likely to result uninformative. We carried out a morphological and immunohistochemical analysis on 22 BRCA1, 16 BRCA2 and 33 BRCAX familial breast cancers. Age at first diagnosis, histological type and grade, and immunostaining for estrogen receptor (ER), progesterone receptor (PR), p53, HER2/Neu, E-cadherin and cyclin D1 were investigated. The occurrence of somatic mutations of the TP53 gene was also verified. BRCA1 tumors resulted clearly distinguishable from BRCAX cases, occurring at a younger age, being more frequently of higher grade, negative for ER, PR and cyclin D1 expression and positive for p53 alterations. The predictive value of age at diagnosis, histological grade and PR expression was confirmed in a multivariable analysis. When comparing BRCA2 with BRCAX tumors, the only parameter that differed was cyclin D1, which was significantly overexpressed in BRCA2 cases both in the univariable and the multivariable analyses. If confirmed by further studies, our observations indicate that the investigation of cyclin D1 expression in familial breast cancer cases could be used, in conjunction with the analysis of other tumor markers preferentially associated with BRCA1 or BRCA2 tumors, to prioritize hereditary cases for mutation testing in BRCA genes.

Original languageEnglish
Pages (from-to)1262-1270
Number of pages9
JournalModern Pathology
Volume21
Issue number10
DOIs
Publication statusPublished - Oct 2008

Fingerprint

Cyclin D1
Progesterone Receptors
Neoplasms
Mutation
Tumor Biomarkers
Estrogen Receptors
BRCA2 Gene
BRCA1 Gene
Germ-Line Mutation
p53 Genes
Cadherins
Genes
Familial Breast Cancer
Breast Neoplasms

Keywords

  • BRCA1
  • BRCA2
  • BRCAX
  • Cyclin D
  • Familial breast cancer

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Cyclin D1 expression analysis in familial breast cancers may discriminate BRCAX from BRCA2-linked cases. / Colombo, Mara; Giarola, Monica; Mariani, Luigi; Ripamonti, Carla B.; De Benedetti, Virna; Sardella, Michele; Losa, Marco; Manoukian, Siranoush; Peissel, Bernard; Pierotti, Marco A.; Pilotti, Silvana; Radice, Paolo.

In: Modern Pathology, Vol. 21, No. 10, 10.2008, p. 1262-1270.

Research output: Contribution to journalArticle

Colombo, Mara ; Giarola, Monica ; Mariani, Luigi ; Ripamonti, Carla B. ; De Benedetti, Virna ; Sardella, Michele ; Losa, Marco ; Manoukian, Siranoush ; Peissel, Bernard ; Pierotti, Marco A. ; Pilotti, Silvana ; Radice, Paolo. / Cyclin D1 expression analysis in familial breast cancers may discriminate BRCAX from BRCA2-linked cases. In: Modern Pathology. 2008 ; Vol. 21, No. 10. pp. 1262-1270.
@article{287c44c3d88d4f2bad248cab605b4dff,
title = "Cyclin D1 expression analysis in familial breast cancers may discriminate BRCAX from BRCA2-linked cases",
abstract = "Most familial breast cancers arise in patients who tested negative for germline mutations in BRCA1 and BRCA2 genes (also referred to as BRCAX cases). Several studies aimed to define histopathological and molecular profiles characteristic of BRCA1, BRCA2 and BRCAX tumors have been performed. Major pathological and immunohistochemical differences have been reported in BRCA1 cancers compared to the other two groups, whereas less difference has been observed between BRCA2 and BRCAX cases. The aim of this study was to investigate the ability of selected tumor markers to discriminate BRCAX breast cancers from cancers arising in carriers of mutations in BRCA genes, and their usefulness in selecting familial cases in whom testing for such mutations is more likely to result uninformative. We carried out a morphological and immunohistochemical analysis on 22 BRCA1, 16 BRCA2 and 33 BRCAX familial breast cancers. Age at first diagnosis, histological type and grade, and immunostaining for estrogen receptor (ER), progesterone receptor (PR), p53, HER2/Neu, E-cadherin and cyclin D1 were investigated. The occurrence of somatic mutations of the TP53 gene was also verified. BRCA1 tumors resulted clearly distinguishable from BRCAX cases, occurring at a younger age, being more frequently of higher grade, negative for ER, PR and cyclin D1 expression and positive for p53 alterations. The predictive value of age at diagnosis, histological grade and PR expression was confirmed in a multivariable analysis. When comparing BRCA2 with BRCAX tumors, the only parameter that differed was cyclin D1, which was significantly overexpressed in BRCA2 cases both in the univariable and the multivariable analyses. If confirmed by further studies, our observations indicate that the investigation of cyclin D1 expression in familial breast cancer cases could be used, in conjunction with the analysis of other tumor markers preferentially associated with BRCA1 or BRCA2 tumors, to prioritize hereditary cases for mutation testing in BRCA genes.",
keywords = "BRCA1, BRCA2, BRCAX, Cyclin D, Familial breast cancer",
author = "Mara Colombo and Monica Giarola and Luigi Mariani and Ripamonti, {Carla B.} and {De Benedetti}, Virna and Michele Sardella and Marco Losa and Siranoush Manoukian and Bernard Peissel and Pierotti, {Marco A.} and Silvana Pilotti and Paolo Radice",
year = "2008",
month = "10",
doi = "10.1038/modpathol.2008.43",
language = "English",
volume = "21",
pages = "1262--1270",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Cyclin D1 expression analysis in familial breast cancers may discriminate BRCAX from BRCA2-linked cases

AU - Colombo, Mara

AU - Giarola, Monica

AU - Mariani, Luigi

AU - Ripamonti, Carla B.

AU - De Benedetti, Virna

AU - Sardella, Michele

AU - Losa, Marco

AU - Manoukian, Siranoush

AU - Peissel, Bernard

AU - Pierotti, Marco A.

AU - Pilotti, Silvana

AU - Radice, Paolo

PY - 2008/10

Y1 - 2008/10

N2 - Most familial breast cancers arise in patients who tested negative for germline mutations in BRCA1 and BRCA2 genes (also referred to as BRCAX cases). Several studies aimed to define histopathological and molecular profiles characteristic of BRCA1, BRCA2 and BRCAX tumors have been performed. Major pathological and immunohistochemical differences have been reported in BRCA1 cancers compared to the other two groups, whereas less difference has been observed between BRCA2 and BRCAX cases. The aim of this study was to investigate the ability of selected tumor markers to discriminate BRCAX breast cancers from cancers arising in carriers of mutations in BRCA genes, and their usefulness in selecting familial cases in whom testing for such mutations is more likely to result uninformative. We carried out a morphological and immunohistochemical analysis on 22 BRCA1, 16 BRCA2 and 33 BRCAX familial breast cancers. Age at first diagnosis, histological type and grade, and immunostaining for estrogen receptor (ER), progesterone receptor (PR), p53, HER2/Neu, E-cadherin and cyclin D1 were investigated. The occurrence of somatic mutations of the TP53 gene was also verified. BRCA1 tumors resulted clearly distinguishable from BRCAX cases, occurring at a younger age, being more frequently of higher grade, negative for ER, PR and cyclin D1 expression and positive for p53 alterations. The predictive value of age at diagnosis, histological grade and PR expression was confirmed in a multivariable analysis. When comparing BRCA2 with BRCAX tumors, the only parameter that differed was cyclin D1, which was significantly overexpressed in BRCA2 cases both in the univariable and the multivariable analyses. If confirmed by further studies, our observations indicate that the investigation of cyclin D1 expression in familial breast cancer cases could be used, in conjunction with the analysis of other tumor markers preferentially associated with BRCA1 or BRCA2 tumors, to prioritize hereditary cases for mutation testing in BRCA genes.

AB - Most familial breast cancers arise in patients who tested negative for germline mutations in BRCA1 and BRCA2 genes (also referred to as BRCAX cases). Several studies aimed to define histopathological and molecular profiles characteristic of BRCA1, BRCA2 and BRCAX tumors have been performed. Major pathological and immunohistochemical differences have been reported in BRCA1 cancers compared to the other two groups, whereas less difference has been observed between BRCA2 and BRCAX cases. The aim of this study was to investigate the ability of selected tumor markers to discriminate BRCAX breast cancers from cancers arising in carriers of mutations in BRCA genes, and their usefulness in selecting familial cases in whom testing for such mutations is more likely to result uninformative. We carried out a morphological and immunohistochemical analysis on 22 BRCA1, 16 BRCA2 and 33 BRCAX familial breast cancers. Age at first diagnosis, histological type and grade, and immunostaining for estrogen receptor (ER), progesterone receptor (PR), p53, HER2/Neu, E-cadherin and cyclin D1 were investigated. The occurrence of somatic mutations of the TP53 gene was also verified. BRCA1 tumors resulted clearly distinguishable from BRCAX cases, occurring at a younger age, being more frequently of higher grade, negative for ER, PR and cyclin D1 expression and positive for p53 alterations. The predictive value of age at diagnosis, histological grade and PR expression was confirmed in a multivariable analysis. When comparing BRCA2 with BRCAX tumors, the only parameter that differed was cyclin D1, which was significantly overexpressed in BRCA2 cases both in the univariable and the multivariable analyses. If confirmed by further studies, our observations indicate that the investigation of cyclin D1 expression in familial breast cancer cases could be used, in conjunction with the analysis of other tumor markers preferentially associated with BRCA1 or BRCA2 tumors, to prioritize hereditary cases for mutation testing in BRCA genes.

KW - BRCA1

KW - BRCA2

KW - BRCAX

KW - Cyclin D

KW - Familial breast cancer

UR - http://www.scopus.com/inward/record.url?scp=52649088203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52649088203&partnerID=8YFLogxK

U2 - 10.1038/modpathol.2008.43

DO - 10.1038/modpathol.2008.43

M3 - Article

C2 - 18327210

AN - SCOPUS:52649088203

VL - 21

SP - 1262

EP - 1270

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 10

ER -